- Home
- PMVP vs TIL Comparison
PMVP vs TIL Comparison
Compare PMVP & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- TIL
- Stock Information
- Founded
- PMVP 2013
- TIL 2018
- Country
- PMVP United States
- TIL United States
- Employees
- PMVP N/A
- TIL N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- TIL Health Care
- Exchange
- PMVP Nasdaq
- TIL Nasdaq
- Market Cap
- PMVP 55.1M
- TIL 230.1M
- IPO Year
- PMVP 2020
- TIL 2021
- Fundamental
- Price
- PMVP $1.25
- TIL $24.49
- Analyst Decision
- PMVP Strong Buy
- TIL Buy
- Analyst Count
- PMVP 1
- TIL 5
- Target Price
- PMVP $5.00
- TIL $119.00
- AVG Volume (30 Days)
- PMVP 230.0K
- TIL 310.3K
- Earning Date
- PMVP 08-07-2025
- TIL 08-12-2025
- Dividend Yield
- PMVP N/A
- TIL N/A
- EPS Growth
- PMVP N/A
- TIL N/A
- EPS
- PMVP N/A
- TIL N/A
- Revenue
- PMVP N/A
- TIL N/A
- Revenue This Year
- PMVP N/A
- TIL N/A
- Revenue Next Year
- PMVP N/A
- TIL N/A
- P/E Ratio
- PMVP N/A
- TIL N/A
- Revenue Growth
- PMVP N/A
- TIL N/A
- 52 Week Low
- PMVP $0.81
- TIL $9.70
- 52 Week High
- PMVP $1.82
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- PMVP 64.21
- TIL 47.69
- Support Level
- PMVP $0.96
- TIL $21.80
- Resistance Level
- PMVP $1.36
- TIL $26.91
- Average True Range (ATR)
- PMVP 0.09
- TIL 3.52
- MACD
- PMVP 0.01
- TIL -0.37
- Stochastic Oscillator
- PMVP 72.22
- TIL 35.14
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.